Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | UBE2M | P61081 | 4/20 | 0.44 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000504 | 0.91 | HPGD (0.66) | HPGDNPC1RAB9ASMN1; SMN2SYK | |
| SCHEMBL16002912 | 0.89 | HPGD (0.56) | HPGDNPC1RAB9ASMN1; SMN2SYK | |
| SCHEMBL13826661 | 0.81 | HPGD (0.52) | HPGDRAB9ASYKALDH1A1MAPT | |
| SCHEMBL16002927 | 0.80 | HPGD (0.69) | HPGDNPC1RAB9ASMN1; SMN2SYK | |
| SCHEMBL31428937 | 0.79 | HPGD (0.60) | HPGDNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL13826454 | 0.75 | HPGD (0.62) | HPGDNPC1RAB9ASMN1; SMN2SYK | |
| SCHEMBL13826112 | 0.75 | NPC1 (0.69) | HPGDNPC1RAB9ALMNAALDH1A1 | |
| SCHEMBL14970147 | 0.74 | HPGD (0.81) | HPGDNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL31429074 | 0.74 | NPC1 (0.57) | HPGDNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL16000517 | 0.74 | DPP4 (0.54) | HPGDNPC1RAB9ASYKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
| WO-2012154518-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | HPGD 829/4885NPC1 3746/4885RAB9A 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.